Tamibarotene: Phase II data

In the ongoing, open-label, U.S. Phase II STAR-1 trial, a 44-year old female APL patient who failed treatment with all-trans retinoic acid (ATRA) and

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE